Indinavir sulphate (Indinavir sulphate)
Overview of Indinavir sulphate
Indinavir (Sulphate) is a protease inhibitor with antiretroviral activity. Indinavir (Sulphate) is used in combintion with other antiretroviral agents for the treatment of HIV infection and with advanced ae progressive immunedefiency.
Indication of Indinavir sulphate
Indinavir Sulphate is primarily indicated in conditions like AIDS, HIV infection, and can also be given in adjunctive therapy as an alternative drug of choice in Prophylaxis after occupational exposure to HIV.
Contraindication of Indinavir sulphate
Indinavir (Sulphate) is contraindicated in conditions like Diabetes mellitus,Haemophilia,Hypersensitivity.
Side Effects of Indinavir sulphate
The severe or irreversible adverse effects of Indinavir (Sulphate), which give rise to further complications include Nausea, Vomiting, Anorexia, Hyperglycemia, Diarrhea, Renal stones, Hyperglycemia, Renal insufficiency, Diabetes mellitus.,Indinavir (Sulphate) produces potentially life-threatening effects which include Anemia, Thrombocytopenia, Bleeding, Anemia, Acute hemolytic anemia, Skin hematomas, Hemarthrosis, Hemarthrosis. which are responsible for the discontinuation of Indinavir (Sulphate) therapy.,The symptomatic adverse reactions produced by Indinavir (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Abdominal distension, Hematuria, Acute renal failure, Weight LossX, Liver dysfunction, Hyperpigmentation, Crystalluria, Hepatitis, Proteinuria, Nephrolithiasis including flank pain, Hepatic failure, Hypertriglyceridemia, Hyperbilirubinemia, Hypercholesterolemia.
Precautions of Indinavir sulphate
Caution is required in diabetic patient, patients with hemophilia who may experienced increased bleeding . Indinavir should be used with caution and possible dose reduction is needed in hepatic impairment. Adequate hydration is recommended to avoid any risk of nephrolithiasis. Monitoring is required in case of renal impairment. Avoid in porphyrid hepatic impairment , Preexisting livered disease or chronic hepatitis B&C treatment may need to be stopped or temperature interupted in patient developing nephrolithasis cuation in a eating pateint with hemeophilis A&B as report of spotaneous Bleeding with use of HIV use of the HIV protease inhibitor